How I treat EBV lymphoproliferation.

Epstein-Barr virus (EBV)-associated B-cell lymphoproliferation is a life-threatening complication after hematopoietic stem cell or solid organ transplantation resulting from outgrowth of EBV-infected B cells that would normally be controlled by EBV-cytotoxic T cells. During the past decade, early detection strategies, such as serial measurement of EBV-DNA load in peripheral blood samples, have helped to identify high-risk patients and to diagnose early lymphoproliferation. Treatment options include manipulation of the balance between outgrowing EBV-infected B cells and the EBV cytotoxic T lymphocyte response and targeting the B cells with monoclonal antibodies or chemotherapy. Major challenges remain for defining indications for preemptive therapies and integrating novel and conventional therapies.

[1]  H. Einsele,et al.  Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia , 2009, Bone Marrow Transplantation.

[2]  R. Reshef,et al.  Rituximab for PTLD of the CNS: Is It a ‘No-Brainer’? , 2008, Oncology Research and Treatment.

[3]  L. Gordon,et al.  Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder , 2008, Transplantation.

[4]  Allen R. Chen,et al.  Successful treatment of a child with late onset T‐cell post‐transplant lymphoproliferative disorder/lymphoma , 2008, Pediatric blood & cancer.

[5]  K. Pritchard-Jones,et al.  Efficacy and tolerability of high‐dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children , 2007, British journal of haematology.

[6]  N. Sebire,et al.  Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation. , 2007, Blood.

[7]  A. Swerdlow,et al.  Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. , 2007, Blood.

[8]  Chiara Bonini,et al.  The suicide gene therapy challenge: how to improve a successful gene therapy approach. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  L. Corey,et al.  Adolescents Are More Likely to Develop Posttransplant Lymphoproliferative Disorder After Primary Epstein-Barr Virus Infection Than Younger Renal Transplant Recipients , 2007, Transplantation.

[10]  F. Baldanti,et al.  Preemptive Therapy of EBV‐Related Lymphoproliferative Disease after Pediatric Haploidentical Stem Cell Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  R. O'reilly,et al.  Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants , 2007, Immunologic research.

[12]  B. Dörken,et al.  Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution , 2007, Annals of Hematology.

[13]  B. Dörken,et al.  Salvage Chemotherapy for Refractory and Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) After Treatment With Single-Agent Rituximab , 2007, Transplantation.

[14]  A. Rickinson,et al.  Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. , 2007, Annual review of immunology.

[15]  C. Klein,et al.  A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. , 2007, Blood.

[16]  U. Jäger,et al.  CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. , 2007, Haematologica.

[17]  P. Veys,et al.  EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning , 2007, Leukemia & lymphoma.

[18]  H. Heslop,et al.  Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high‐risk for EBV infection , 2006, Clinical transplantation.

[19]  H. Heslop,et al.  Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). , 2006, Blood.

[20]  J. Wagner,et al.  Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. , 2006, Blood.

[21]  D. van Baarle,et al.  Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  G. Salles,et al.  Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. , 2006, Blood.

[23]  B. Dörken,et al.  Effect of Anti‐CD 20 Antibody Rituximab in Patients with Post‐Transplant Lymphoproliferative Disorder (PTLD) , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  Michael D. Green,et al.  Posttransplant lymphoproliferative disease. , 2005, The Pediatric infectious disease journal.

[25]  D. Dunn,et al.  Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation , 2005, Cancer.

[26]  T. Greiner,et al.  Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  H. Heslop,et al.  Quantitative EBV Viral Loads and Immunosuppression Alterations can Decrease PTLD Incidence in Pediatric Liver Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  E. Woodle,et al.  Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. , 2005, Transplantation proceedings.

[29]  H. Heslop,et al.  Cellular Immunity to Epstein‐Barr Virus in Liver Transplant Recipients Treated with Rituximab for Post‐Transplant Lymphoproliferative Disease , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  G. Palù,et al.  The real‐time polymerase chain reaction‐guided modulation of immunosuppression enables the pre‐emptive management of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation , 2005, British journal of haematology.

[31]  R. Krance,et al.  Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. , 2004, Transplantation.

[32]  R. Krance,et al.  Prompt versus preemptive intervention for EBV lymphoproliferative disease. , 2004, Blood.

[33]  D. Thorley-Lawson,et al.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas. , 2004, The New England journal of medicine.

[34]  S. Grupp,et al.  An unexpectedly high incidence of Epstein–Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma , 2004, Bone Marrow Transplantation.

[35]  C. Chang,et al.  Humanized anti‐CD20 monoclonal antibody (Rituximab) treatment for post‐transplant lymphoproliferative disorder * , 2003, Clinical transplantation.

[36]  F. Miedema,et al.  Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. , 2003, Blood.

[37]  C. Garcia,et al.  Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment , 2003, Transplant international : official journal of the European Society for Organ Transplantation.

[38]  G. Remuzzi,et al.  Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome , 2002, Transplantation.

[39]  B. van der Holt,et al.  Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. , 2002, Blood.

[40]  H. Bazin,et al.  Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease1 , 2002, Transplantation.

[41]  Paul Martin,et al.  A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. , 2002, Blood.

[42]  F. Baldanti,et al.  Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. , 2002, Blood.

[43]  S. Kenney,et al.  Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. , 2002, Cancer research.

[44]  V. Ribrag,et al.  Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. , 2001, The New England journal of medicine.

[45]  B. van der Holt,et al.  Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT. , 2001, Blood.

[46]  B. Somer,et al.  REDUCTION IN IMMUNOSUPPRESSION AS INITIAL THERAPY FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: ANALYSIS OF PROGNOSTIC VARIABLES AND LONG-TERM FOLLOW-UP OF 42 ADULT PATIENTS1 , 2001, Transplantation.

[47]  P. Furth,et al.  Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system , 2000, The Lancet.

[48]  B. O'neill,et al.  Posttransplant primary CNS lymphoma. , 2000, Neuro-oncology.

[49]  Zhensheng Liu,et al.  CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. , 2000, Blood.

[50]  I. Ernberg,et al.  Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. , 2000, Blood.

[51]  E. Kieff,et al.  Epstein-barr virus-induced posttransplant lymphoproliferative disorders , 1999 .

[52]  Richard E. Slaughter,et al.  Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[53]  R. Freeman,et al.  Epstein-Barr Virus–Infected Resting Memory B Cells, Not Proliferating Lymphoblasts, Accumulate in the Peripheral Blood of Immunosuppressed Patients , 1999, The Journal of experimental medicine.

[54]  G. Ogg,et al.  Direct Visualization of Antigen-specific CD8+T Cells during the Primary Immune Response to Epstein-Barr Virus In Vivo , 1998, The Journal of experimental medicine.

[55]  A. Kliger,et al.  Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. , 1997, Transplantation.

[56]  K. Lucas,et al.  Biology and adoptive cell therapy of Epstein‐Barr virus‐associated lymphoproliferative disorders in recipients of marrow allografts , 1997, Immunological reviews.

[57]  Malcolm K. Brenner,et al.  Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.

[58]  R. Krance,et al.  Early identification of Epstein‐Barr virus‐associated post‐transplantation lymphoproliferative disease , 1995, British journal of haematology.

[59]  H. Heslop,et al.  Donor T cells to treat EBV-associated lymphoma. , 1994, The New England journal of medicine.

[60]  R. Krance,et al.  Epstein-Barr infection after bone marrow transplantation. , 1994, Blood.

[61]  M. Nalesnik Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. , 2002, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[62]  J. Hurwitz,et al.  T cell immunotherapeutic populations control viral infections in bone marrow transplant recipients , 2001, Immunologic research.

[63]  I. Flinn,et al.  Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. , 2000, Blood.

[64]  E. Kieff,et al.  Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. , 1999, Transplantation.

[65]  D. Srivastava,et al.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.

[66]  J. Yates,et al.  Stable replication of plasmids derived from Epstein–Barr virus in various mammalian cells , 1985, Nature.